At Qubiotech we develop cloud based software for the automatic analysis of neuroimaging: Neurocloud, a tool for quantifying biomarkers in neurodegenerative diseases, which quickly, accurately and effectively helps the doctor (radiologist, neurologist and nuclear medicine) in the diagnosis and follow-up of the patient providing a complete report of the results in few minutes. The application, Neurocloud, which stands out for its very intuitive interface, offers clinically validated results (CE Marking and FDA in progress) that help diagnose increasingly common diseases such as Parkinson's, Alzheimer's, Epilepsy or Multiple Sclerosis. Neurocloud quantification allows us to go from subjective evaluations, which depend on the observer, to quantitative, reproducible evaluations, and therefore members of the same team can reach the same results with confidence. Qubiotech is a company that emerged in 2014 from the Molecular Imaging Research Group of the Hospital ClÃnico de Santiago de Compostela with the aim of bringing innovation in molecular image analysis to real clinical practice and also at a very low cost compared to the alternatives that we had until now. Furthermore, at Qubiotech we want to be the world reference in neuroimaging software, growing with the incorporation of the latest technologies such as deep learning or artificial intelligence, and collaborating in pioneering scientific research in the field of medical imaging.